Drug Trial Radar · NCT04573192
A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
Last checked: Nov 19, 2026Latest source record: Apr 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
142
Planned (sponsor's estimate)
Start
Feb 19, 2021
Primary completion
Mar 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Philogen S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Glioblastomas are the most common and most aggressive primary brain tumors in adults. The prognosis is poor despite multimodal therapy with surgery, radiotherapy and chemotherapy. Therefore, novel treatments are urgently needed. L19TNF is a fully human fusion protein consisting of human tumor necrosis factor (TNF)-α fused to the L19 antibody in scFv format, specific to the extra-domain B of fibronectin. TNF not only induces apoptosis or necrosis in certain target cells, but also exerts inflammation and immunity. L19TNF selectively delivers TNF to the tumor site to spare normal tissues from undesired toxicity. Preclinical experiments with L19TNF have demonstrated tumor growth retardation in various mouse tumor models including models of glioma.
Conditions
- Glioblastoma
Interventions
L19TNFDrug
Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
LomustineDrug
Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
Primary outcomes
What the sponsor says the trial is designed to measure.
- For Phase 1: DLTTime frame: For Cohort 1 to Cohort 3 from Day 1 to Day 42 after the first administration of lomustine and study drug (Cycle 1)
- For Phase 2: Overall SurvivalTime frame: From beginning of treatment to 12 months
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Hôpital Neurologique Pierre Wertheimer
Bron, France · Not yet recruiting
Hôpital Saint Louis
Paris, France · Not yet recruiting
Sorbonne University, AP-HP, Paris brain institute
Paris, France · Not yet recruiting
University Hospital Bonn
Bonn, Germany · Recruiting
University Hospital Köln
Cologne, Germany · Not yet recruiting
Klinikum rechts der Isar
München, Germany · Recruiting
Universitatsklinikum Tubingen
Tübingen, Germany · Recruiting
Azienda USL di Bologna IRCCS delle Scienze Neurologiche di Bologna
Bologna, Italy · Recruiting
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy · Recruiting
Istituto Oncologico Veneto IRCCS
Padova, Italy · Recruiting
Azienda Ospedaliero-Universitaria Senese Policlinico Le Scotte
Siena, Italy · Not yet recruiting
AOU Città della Salute e della Scienza di Torino
Torino, Italy · Not yet recruiting
Inselspital Universitätsklinik für Medizinische Onkologie Bern
Bern, Switzerland · Recruiting
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland · Recruiting
Universitatspital Zurich - Klinik fur Neurologie & Hirntumorzentrum
Zurich, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.